POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
批准号:
3853335
负责人:
J E JANIK
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
antiviral agents clinical trials combination cancer therapy dosage double stranded RNA drug adverse effect drug tolerance enzyme induction /repression enzyme inhibitors human subject human therapy evaluation human tissue hypotension interferon inducers interferons kidney neoplasms melanoma neoplasm /cancer immunotherapy phosphorylation poly IC rectum neoplasms
中文摘要
干扰素可诱导大量基因产物的合成。
这些产品起到了抗病毒和抗增殖的作用
α干扰素的作用。其中两种诱导基因产物,
2‘,5’-寡腺苷合成酶和双链抑制物(DSI)
由干扰素诱导,但需要双链RNA才能激活
他们。DSI在抑制蛋白质合成方面起主要作用
真核细胞启动因子2(eIF-2)的磷酸化
在其阿尔法亚基的丝氨酸51上。
这项研究联合使用干扰素α和Poly ICLC,a
形成双链RNA以确定最佳剂量水平
干扰素诱导DSI及Poly ICLC的最佳剂量
用于激活该激活酶。三个剂量水平的干扰素是
与Poly ICLC的四个剂量水平之一相结合。
这项研究旨在确定这种组合的毒性。
和最大耐受量。观察到剂量限制毒性。
干扰素10mU/m2+Poly ICLC 0.03 mg/m2。
毒性包括长期低血压,需要住院治疗
用于静脉输液。允许更高剂量的Poly ICLC
在不使用干扰素的情况下,以10mU/m2剂量水平给予干扰素
毒性。这些结果表明,Poly ICLC在
低剂量或高剂量的ICLC可能会降低
干扰素。
英文摘要
Interferon induces the synthesis of a large number of gene products.
These products play a role in the antiviral and antiproliferative
effects of alpha interferon. Two of the induced gene products,
2',5'-oligoadenylate synthetase and the double-stranded inhibitor (DSI)
are induced by interferon but require double-stranded RNA to activate
them. The DSI plays a major role in inhibiting protein synthesis
initiation by phosphorylating the eukaryotic initiation factor 2 (eIF-2)
on serine 51 of its alpha subunit.
This study combined administration of interferon alpha and Poly ICLC, a
form of double-stranded RNA in order to determine the optimal dose level
of interferon for induction of the DSI and the optimal dose of Poly ICLC
for activation of the kinase. Three dose levels of interferon were
combined with one of four dose levels of Poly ICLC.
This study was designed to determine the toxicity of this combination
and the maximal tolerated dose. Dose limiting toxicity was observed
with the combination of interferon 10 mu/m2 and Poly ICLC 0.03 mg/m2.
Toxicity consisted of prolonged hypotension requiring hospitalization
for intravenous fluid administration. Higher doses of Poly ICLC allowed
administration of interferon at the 10 mu/m2 dose level without this
toxicity. These results suggest that Poly ICLC may be more toxic at
lower doses or that higher doses of ICLC may reduce the toxicity of
interferon.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:2464506
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
-
批准号:3874539
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH R-INTERFERON GAMMA
-
批准号:2464513
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I TRIAL OF TNF AND GM-CSF
-
批准号:3752523
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
-
批准号:3752507
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A (R022-8181/002) IN HAIRY CELL LEUKEMIA
-
批准号:3752481
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3838223
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
-
批准号:3853339
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER
-
批准号:3752508
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
-
批准号:3838227
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
-
批准号:3838238
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:6163345
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER
-
批准号:3838239
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE INTERFERON ALPHA IN HCL
-
批准号:2464504
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:6163429
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE A IFN IN HAIRY CELL LEUKEMIA
-
批准号:3752475
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH RIFN-GAMMA
-
批准号:3752495
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3752497
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3874559
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
-
批准号:3853315
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
海外基金